297 results on '"Palmieri, Raffaele"'
Search Results
2. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia
3. Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
4. Allogeneic stem cell transplantation in patients with a prior history of prostate cancer
5. Enhanced recovery after surgery (ERAS) program in octogenarian patients: a propensity score matching analysis on the “Lazio Network” database
6. CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML
7. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
8. Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis
9. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
10. Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy
11. Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle
12. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study
13. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
14. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study
15. Impact of implementation of the ERAS program in colorectal surgery: a multi-center study based on the “Lazio Network” collective database
16. THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION.
17. P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
18. P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
19. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
20. Editorial: Measurable residual disease in hematologic malignancies
21. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
22. Acute leukemia diagnosis during the COVID-19 pandemic
23. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
24. FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS.
25. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms
26. Editorial: Measurable residual disease in hematologic malignancies
27. Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
28. Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
29. Allogeneic stem cell transplantation in patients with a prior history of prostate cancer
30. Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
31. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
32. The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis
33. The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials
34. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
35. Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients
36. Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
37. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy
38. Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
39. Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
40. The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
41. Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia.
42. In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
43. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
44. Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms
45. Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter, Cohort Study
46. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia
47. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia
48. Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia
49. Prevalence and Genotyping of Pneumocystis jirovecii Pneumonia in Patients with Previously Untreated Acute Myeloid Leukemia
50. Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.